DK2903618T3 - Rho-kinase-inhibitorer - Google Patents

Rho-kinase-inhibitorer Download PDF

Info

Publication number: DK2903618T3
Authority: DK; Denmark
Prior art keywords: kinase inhibitors; rho kinase; rho; inhibitors; kinase
Prior art date: 2012-10-05

Application number

DK13843426.1T

Other languages

English (en)

Inventor

Ji-In Kim

Kevin Liu

Alexandra Zanin-Zhorov

Masha Poyurovsky

Original Assignee

Kadmon Corp Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-10-05

Filing date

2013-10-07

Publication date

2022-08-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50435589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2903618(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-10-07 Application filed by Kadmon Corp Llc filed Critical Kadmon Corp Llc

2022-08-22 Application granted granted Critical

2022-08-22 Publication of DK2903618T3 publication Critical patent/DK2903618T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Dermatology (AREA)
Ophthalmology & Optometry (AREA)
Epidemiology (AREA)
Hematology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Gastroenterology & Hepatology (AREA)
Gynecology & Obstetrics (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Transplantation (AREA)

DK13843426.1T 2012-10-05 2013-10-07 Rho-kinase-inhibitorer DK2903618T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261710373P	2012-10-05	2012-10-05
US201361840288P	2013-06-27	2013-06-27
PCT/US2013/063752 WO2014055996A2 (en)	2012-10-05	2013-10-07	Rho kinase inhibitors

Publications (1)

Publication Number	Publication Date
DK2903618T3 true DK2903618T3 (da)	2022-08-22

Family

ID=50435589

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK13843426.1T DK2903618T3 (da)	2012-10-05	2013-10-07	Rho-kinase-inhibitorer

Country Status (16)

Country	Link
US (4)	US9815820B2 (da)
EP (2)	EP4116293A3 (da)
JP (2)	JP6419076B2 (da)
CN (5)	CN113637008A (da)
CA (2)	CA2926478C (da)
DK (1)	DK2903618T3 (da)
EA (1)	EA201500362A1 (da)
ES (1)	ES2924915T3 (da)
HR (1)	HRP20220913T1 (da)
HU (1)	HUE059305T2 (da)
LT (1)	LT2903618T (da)
PL (1)	PL2903618T3 (da)
PT (1)	PT2903618T (da)
RS (1)	RS63503B1 (da)
SI (1)	SI2903618T1 (da)
WO (1)	WO2014055996A2 (da)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11008359B2 (en)	2002-08-23	2021-05-18	Illumina Cambridge Limited	Labelled nucleotides
PL2903618T3 (pl)	2012-10-05	2022-09-19	Kadmon Corporation, Llc	Inhibitory kinazy rho
WO2015157556A1 (en) *	2014-04-09	2015-10-15	Kadmon Corporation, Llc	Treatment of gvhd
JP6633618B2 (ja)	2014-08-21	2020-01-22	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	強力なｒｏｃｋ阻害剤としてのタイドバックのベンズアミド誘導体
WO2016057726A2 (en) *	2014-10-07	2016-04-14	Kadmon Corporation, Llc	Human anti-vegfr-2/kdr antibodies
EP3262041A4 (en)	2015-02-27	2018-08-01	Lycera Corporation	Indazolyl thiadiazolamines and related compounds for inhibition of rho-associated protein kinase and the treatment of disease
US11021468B2 (en) *	2015-04-01	2021-06-01	Rigel Pharmaceuticals, Inc.	TGF-ß inhibitors
CA2987071A1 (en)	2015-06-10	2016-12-15	Hackensack University Medical Center	Use of telmisartan to prevent and treat graft versus host disease and other alloimmune and autoimmune diseases
EA201890153A1 (ru) *	2015-06-26	2018-06-29	КАДМОН КОРПОРЕЙШН, ЭлЭлСи	Ингибиторы поглощения глюкозы
CN109310755A (zh) *	2016-02-02	2019-02-05	卡德门企业有限公司	Pd-l1和kdr的双特异性结合蛋白
EP3496748A4 (en) *	2016-08-05	2020-01-15	Medimmune, LLC	ANTI-O2 ANTIBODIES AND USES THEREOF
EP3504204A4 (en)	2016-08-26	2020-05-27	Lycera Corporation	INDAZOLYL-L, 2,4-THIADIAZOLAMINE AND RELATED COMPOUNDS FOR INHIBITING RHO-ASSOCIATED PROTEIN KINASES AND FOR TREATING DISEASES
KR20190064636A (ko)	2016-10-19	2019-06-10	메디뮨 엘엘씨	항-o1 항체 및 이의 용도
CN106916145B (zh) *	2017-03-06	2019-06-04	上海应用技术大学	SLx-2119的合成方法
IT201700047189A1 (it) *	2017-05-02	2018-11-02	Fondazione St Italiano Tecnologia	Composti e composizioni per il trattamento di cancro, disordini della retina e cardiomiopatie
AU2018294054B2 (en) *	2017-06-30	2022-05-26	Beijing Tide Pharmaceutical Co., Ltd.	Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
WO2019000683A1 (zh) *	2017-06-30	2019-01-03	北京泰德制药股份有限公司	Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
CN110573501B (zh) *	2017-06-30	2023-09-29	北京泰德制药股份有限公司	Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
EA202090572A1 (ru) *	2017-09-01	2020-07-06	Кадмон Корпорейшн, Ллк	ИНГИБИТОРЫ Rho-АССОЦИИРОВАННОЙ, СОДЕРЖАЩЕЙ СУПЕРСПИРАЛЬ ПРОТЕИНКИНАЗЫ
JP2020532551A (ja)	2017-09-03	2020-11-12	アンジオンバイオメディカコーポレーション	Ｒｈｏ関連コイルドコイルキナーゼ（ＲＯＣＫ）阻害剤としてのビニルヘテロ環
WO2019201297A1 (zh)	2018-04-18	2019-10-24	南京明德新药研发有限公司	作为rho激酶抑制剂的苯并吡唑类化合物
PT3877364T (pt)	2018-11-06	2024-11-05	Cervello Therapeutics LLC	Inibidores de rock cinase
US11248004B2 (en)	2018-11-06	2022-02-15	Cervello Therapeutics, Llc.	Substituted isoquinolines as rock kinase inhibitors
US20220202827A1 (en) *	2019-04-08	2022-06-30	The General Hospital Corporation	Enhancement of Melanocyte Migration Using ROCK Inhibitors
JP7252417B2 (ja)	2019-10-18	2023-04-04	メッドシャインディスカバリーインコーポレイテッド	Ｒｈｏキナーゼ阻害剤としてのベンゾピラゾール化合物の塩形、結晶形及びその製造方法
CN114746412A (zh) *	2019-12-27	2022-07-12	广东东阳光药业有限公司	Kd-025的新晶型及其制备方法
US12014835B2 (en)	2020-02-19	2024-06-18	Vanderbilt University	Methods for evaluating therapeutic benefit of combination therapies
KR20230043891A (ko) *	2020-07-22	2023-03-31	베이징 타이드 파마슈티컬 코퍼레이션 리미티드	조혈 줄기 세포 이식으로 인한 이식편대숙주병의 치료 방법
CN116390918B (zh)	2020-07-22	2024-12-24	梯瓦制药国际有限责任公司	Belumosudil和belumosudil盐的固态形式
WO2022042666A1 (zh) *	2020-08-28	2022-03-03	杭州邦顺制药有限公司	选择性rock2激酶抑制剂
MX2023008141A (es)	2021-01-11	2023-10-20	Incyte Corp	Terapia combinada que comprende el inhibidor de la vía de proteínas tirosina cinasas de janus cinasas (jak) y el inhibidor de la proteína cinasa asociada a rho (rock).
WO2022170864A1 (zh) *	2021-02-09	2022-08-18	苏州科睿思制药有限公司	Belumosudil甲磺酸盐的晶型及其制备方法和用途
WO2022229351A1 (en)	2021-04-28	2022-11-03	Graviton Bioscience Bv	Selective inhibitors of rock2 for the treatment of muscular dystrophy
WO2023285706A1 (en)	2021-07-16	2023-01-19	Sandoz Ag	Solid-state forms of 2-(3-(4-(1h-indazol-5-ylamino)quinazolin-2-yl )phenoxy)-n- isopropylacetamide methane sulfonic acid salt
US20250000083A1 (en)	2021-11-11	2025-01-02	The Doshisha	Cryopreservation preparation for corneal endothelial cells and method for producing said cryopreservation preparation
CN119031914A (zh)	2022-04-19	2024-11-26	卡德门企业有限公司	贝鲁舒地尔用于治疗慢性肺同种异体移植功能障碍
CA3178096A1 (en)	2022-07-14	2024-01-14	Kadmon Corporation, Llc	Methods of administering belumosudil for treatment of chronic graft versus host disease
WO2024015065A1 (en)	2022-07-14	2024-01-18	Kadmon Corporation, Llc	Methods of administering belumosudil for treatment of chronic graft versus host disease in patient subpopulations
WO2024015066A1 (en)	2022-07-14	2024-01-18	Kadmon Corporation, Llc	Methods of administering belumosudil in combination with cyp3a inducers and/or proton pump inhibitors
CA3178085A1 (en)	2022-07-14	2024-01-14	Kadmon Corporation, Llc	Belumosudil metabolites and uses thereof in the treatment of chronic graft-versus-host disease
WO2024023276A1 (en)	2022-07-27	2024-02-01	Graviton Bioscience Bv	Rock2 inhibitors for the treatment of viral infections
WO2024063770A1 (en) *	2022-09-21	2024-03-28	Kadmon Corporation, Llc	Liquid formulation of belumosudil
CN117243959A (zh) *	2022-10-13	2023-12-19	山东大学	治疗骨质疏松的方法和药物组合物
WO2024110851A1 (en) *	2022-11-21	2024-05-30	Graviton Bioscience Bv	Inhibitors of rock2
WO2024118556A1 (en)	2022-11-29	2024-06-06	Kadmon Corporation, Llc	Solid dispersion comprising amorphous 2-[3-[4-(lh-indazol-5- ylamino)quinazolin-2-yl]phenoxy]-n-propan-2-yl-acetamide
WO2024124084A1 (en)	2022-12-09	2024-06-13	Kadmon Corporation, Llc	Methods of administering belumosudil for treatment of multiple myeloma
WO2025017499A1 (en)	2023-07-17	2025-01-23	Graviton Bioscience Bv	Formulations and uses of rock2 inhibitors for als

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS59115488A (ja) *	1982-12-22	1984-07-03	Hitachi Ltd	密閉形スクロ−ル圧縮機の軸受装置
WO2003062225A1 (en) *	2002-01-23	2003-07-31	Bayer Pharmaceuticals Corporation	Pyrimidine derivatives as rho-kinase inhibitors
EP1781293A1 (en)	2004-06-04	2007-05-09	Amphora Discovery Corporation	Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
CR9465A (es) *	2005-03-25	2008-06-19	Surface Logix Inc	Compuestos mejorados farmacocineticamente
US8216575B2 (en)	2006-03-31	2012-07-10	Chengdu Kanghong Biotechnologies Co., Ltd.	Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
CA2700988A1 (en) *	2006-09-27	2008-05-08	Surface Logix, Inc.	Rho kinase inhibitors
US8648069B2 (en)	2007-06-08	2014-02-11	Abbvie Inc.	5-substituted indazoles as kinase inhibitors
CN104530052A (zh) *	2008-06-10	2015-04-22	普莱希科公司	用于激酶调节的5h-吡咯[2,3-b]吡嗪衍生物和其适应症
WO2011062766A2 (en) *	2009-11-17	2011-05-26	The Regents Of The University Of Michigan	1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
EP2626348A1 (en) *	2010-03-02	2013-08-14	Amakem NV	Heterocyclic amides as rock inhibitors
US9079880B2 (en) *	2010-07-07	2015-07-14	Boehringer Ingelheim International Gmbh	Rho kinase inhibitors
WO2012040499A2 (en) *	2010-09-22	2012-03-29	Surface Logix, Inc.	Metabolic inhibitors
JP6117104B2 (ja)	2010-11-15	2017-04-19	アッヴィ・インコーポレイテッド	Ｎａｍｐｔおよびｒｏｃｋ阻害薬
GB201107223D0 (en)	2011-04-29	2011-06-15	Amakem Nv	Novel rock inhibitors
GB201114854D0 (en)	2011-08-29	2011-10-12	Amakem Nv	Novel rock inhibitors
PT2751080E (pt)	2011-08-31	2016-03-04	Amakem Nv	Inibidores leves de rock
PL2903618T3 (pl) *	2012-10-05	2022-09-19	Kadmon Corporation, Llc	Inhibitory kinazy rho
EA201500364A1 (ru) *	2012-10-05	2015-08-31	Кадмон Корпорейшн, Ллк	Лечение глазных заболеваний
WO2015157556A1 (en) *	2014-04-09	2015-10-15	Kadmon Corporation, Llc	Treatment of gvhd

2013
- 2013-10-07 PL PL13843426.1T patent/PL2903618T3/pl unknown
- 2013-10-07 CN CN202110707587.XA patent/CN113637008A/zh active Pending
- 2013-10-07 US US14/431,936 patent/US9815820B2/en active Active
- 2013-10-07 EP EP22175888.1A patent/EP4116293A3/en active Pending
- 2013-10-07 WO PCT/US2013/063752 patent/WO2014055996A2/en active Application Filing
- 2013-10-07 CN CN201380063599.7A patent/CN105120869A/zh active Pending
- 2013-10-07 HU HUE13843426A patent/HUE059305T2/hu unknown
- 2013-10-07 SI SI201332003T patent/SI2903618T1/sl unknown
- 2013-10-07 CA CA2926478A patent/CA2926478C/en active Active
- 2013-10-07 CN CN202110707555.XA patent/CN113637007A/zh active Pending
- 2013-10-07 CA CA3151343A patent/CA3151343A1/en active Pending
- 2013-10-07 EA EA201500362A patent/EA201500362A1/ru unknown
- 2013-10-07 RS RS20220776A patent/RS63503B1/sr unknown
- 2013-10-07 HR HRP20220913TT patent/HRP20220913T1/hr unknown
- 2013-10-07 DK DK13843426.1T patent/DK2903618T3/da active
- 2013-10-07 ES ES13843426T patent/ES2924915T3/es active Active
- 2013-10-07 CN CN202110707706.1A patent/CN113620933A/zh active Pending
- 2013-10-07 EP EP13843426.1A patent/EP2903618B1/en active Active
- 2013-10-07 PT PT138434261T patent/PT2903618T/pt unknown
- 2013-10-07 LT LTEPPCT/US2013/063752T patent/LT2903618T/lt unknown
- 2013-10-07 JP JP2015535880A patent/JP6419076B2/ja active Active
- 2013-10-07 CN CN202110707631.7A patent/CN113773308A/zh active Pending
2017
- 2017-11-10 US US15/809,460 patent/US10183931B2/en active Active
2018
- 2018-10-09 JP JP2018191181A patent/JP6703075B2/ja active Active
2019
- 2019-01-18 US US16/251,952 patent/US10696660B2/en active Active
2020
- 2020-06-26 US US16/913,267 patent/US20210147391A1/en active Pending

Also Published As

Publication number	Publication date
US20190308953A1 (en)	2019-10-10
SI2903618T1 (sl)	2022-09-30
CN113637007A (zh)	2021-11-12
LT2903618T (lt)	2022-08-25
WO2014055996A3 (en)	2014-06-19
EA201500362A1 (ru)	2015-08-31
JP6703075B2 (ja)	2020-06-03
WO2014055996A2 (en)	2014-04-10
CA3151343A1 (en)	2014-04-10
CN113620933A (zh)	2021-11-09
HUE059305T2 (hu)	2022-11-28
US9815820B2 (en)	2017-11-14
RS63503B1 (sr)	2022-09-30
HRP20220913T1 (hr)	2022-10-28
US10183931B2 (en)	2019-01-22
CN113773308A (zh)	2021-12-10
US20150252025A1 (en)	2015-09-10
CN113637008A (zh)	2021-11-12
EP2903618A2 (en)	2015-08-12
EP4116293A3 (en)	2023-03-29
JP6419076B2 (ja)	2018-11-14
US20180244657A1 (en)	2018-08-30
US10696660B2 (en)	2020-06-30
PT2903618T (pt)	2022-08-19
PL2903618T3 (pl)	2022-09-19
CA2926478C (en)	2022-05-24
EP4116293A2 (en)	2023-01-11
JP2019034949A (ja)	2019-03-07
JP2015533125A (ja)	2015-11-19
EP2903618A4 (en)	2017-05-10
EP2903618B1 (en)	2022-06-01
US20210147391A1 (en)	2021-05-20
CN105120869A (zh)	2015-12-02
CA2926478A1 (en)	2014-04-10
ES2924915T3 (es)	2022-10-11

Publication	Publication Date	Title
DK2903618T3 (da)	2022-08-22	Rho-kinase-inhibitorer
CO6970602A2 (es)	2014-06-13	Inhibidores de quinasa
EP2710007A4 (en)	2015-04-01	Kinase inhibitors
LT3181567T (lt)	2019-07-25	Pirazolpirimidino junginiai kaip kinazės slopikliai
HK1214813A1 (zh)	2016-08-05	激酶抑制劑
LT2841428T (lt)	2018-12-10	Dnr-pk inhibitoriai
DK2895484T3 (da)	2022-05-09	Glucosylceramidsynthase-inhibitorer
DK3321262T3 (da)	2021-01-25	Serin-/threoninkinasehæmmere
ME02626B (me)	2017-06-20	Inhibitori neprilisina
SMT201600114B (it)	2016-08-31	Inibitori di beta-secretasi
CO6950481A2 (es)	2014-05-20	Inhibidores de proteínas quinasas
RS56821B1 (sr)	2018-04-30	Inhibitori histon demetilaze
IL230561A0 (en)	2014-03-31	Inhibitors of bruton's tyrosine kinsae
HUE056999T2 (hu)	2022-04-28	Pirazolil-kinoxalin kináz inhibitorok
DK2917210T3 (da)	2019-05-27	Alk kinase-inhibitorer
HUE036259T2 (hu)	2018-06-28	Inhibitor vegyületek
CO6880068A2 (es)	2014-02-28	Aminoquinazolinas como inhibidores de quinasa
IL228311A0 (en)	2013-11-25	Protein kinase inhibitors
BR112014033056A2 (pt)	2017-06-27	inibidores da proteína quinase
CO6990735A2 (es)	2014-07-10	Inhibidores de pirazina cinasa
SMT201600357B (it)	2016-11-10	Inibitori di iap
HUE036347T2 (hu)	2018-07-30	Aminokinazolin-kináz-inhibitor prodrogjai
BR112014029718A2 (pt)	2017-06-27	inibidores da proteína quinase
BR112015002078A2 (pt)	2017-07-04	inibidores antibacteriais de proteína quinase
EP2847201A4 (en)	2016-03-09	6-oxo-purin-phosphoribosyl INHIBITORS